desloratadine / Generic mfg. - LARVOL DELTA

The effects of oral second-generation antihistamines on psychomotor, cognitive, and academic performance: A systematic review (AAAAI 2026) - "Search terms included oral second-generation antihistamines approved for use in the United States and Canada, specifically cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine, bilastine, and rupatadine, with the terms psychomotor, cognitive, and academic performance. Varying effects were found across these categories. Understanding these outcomes will better inform patient care via appropriate selection of antihistamines to minimize disruption on daily activities."

Review • Anesthesia

UC: Desloratadine in Patients With Ulcerative Colitis (clinicaltrials.gov) - P2 | N=44 | Recruiting | Sponsor: Tanta University | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial. (PubMed, Cancer) - P2 | "To the authors' knowledge, this is the first study to prospectively present that aprepitant elicited a better and faster response and mild toxicity for managing EGFR-TKI induced pruritus than desloratadine."

Clinical • Journal • P2 data • Constipation • Dermatology • Gastroenterology • Gastrointestinal Disorder • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pruritus • Solid Tumor • Xerostomia • EGFR

Administration of Desloratadine for Postorgasmic Illness Syndrome in a Japanese Teenager. (PubMed, IJU Case Rep) - "A Japanese teenager suffering from postorgasmic illness syndrome was successfully treated with desloratadine. We believe that our experience will contribute to elucidating and treating this condition in the future."

Journal • CNS Disorders • Depression • Fatigue • Pain • Psychiatry

Optical control of H1 receptor signaling with a BODIPY-photocaged antihistamine. (PubMed, Biochem Pharmacol) - "Irradiation of 1 with 560 nm light results in photo-uncaging and the release of the parent drug desloratadine, resulting in optical modulation of histamine-induced H1R signaling. The presented BODIPY-based photocaging of desloratadine offers a powerful new tool for the precise optical control of H1R function."

Journal • Allergy

UC: Desloratadine in Patients With Ulcerative Colitis (clinicaltrials.gov) - P2 | N=44 | Not yet recruiting | Sponsor: Tanta University

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Efficacy of a Combination Therapy of Montelukast and Antihistamines in Allergic Rhinitis: A Systematic Review and Network Meta-Analysis. (PubMed, Allergy Asthma Immunol Res) - "The treatment strategies included montelukast alone, antihistamine monotherapies (loratadine, desloratadine, levocetirizine, and fexofenadine), their respective combinations with montelukast, including bilastine. Although some comparisons require cautious interpretation, montelukast-based combination therapy demonstrated greater efficacy than monotherapy for multiple AR symptoms. These results highlight the importance of selecting therapeutic strategies based on the predominant symptom profile of individual patients."

Journal • Retrospective data • Review • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Investigation of the Immune System Effects of Desloratadine on Lipopolysaccharide-Stimulated Mammalian Macrophage Cells. (PubMed, Fundam Clin Pharmacol) - "DES selectively modulates macrophage responses, strongly inhibiting TNF-α and IL-12p40 while enhancing GM-CSF, reflecting a dual anti- and pro-inflammatory profile. These findings support further investigation of DES in neuroinflammatory and immune-mediated conditions."

Journal • CNS Disorders • Immunology • Inflammation • IL6 • TNFA

Desloratadine Induces TP53-Dependent Apoptosis in MCF-7 Breast Cancer Cells. (PubMed, Cells) - "Compared with wild-type cells, these knockout cells displayed markedly reduced sensitivity to Desloratadine, with the IC50 shifting from 14.2 µg/mL to 36.4 µg/mL, demonstrating that p53 is a key mediator of the drug's cytotoxic effect. Collectively, these findings identify Desloratadine as a potential repurposed drug candidate for breast cancer therapy, acting at least in part through a p53-dependent apoptotic pathway."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • ANXA5 • BCL2 • PARP1 • STAT3 • TP53

Differential modulation of cisplatin efficacy by montelukast sodium and desloratadine in lung cancer. (PubMed, Turk J Biol) - "These findings support the potential of MLS as an effective adjuvant in CIS-based lung cancer treatment. However, the antagonistic effect observed with DES highlights the importance of careful evaluation of candidates for drug repurposing."

Journal • Lung Cancer • Oncology • Solid Tumor • GPX4

Impact of Desloratadine on Treatment Response and Inflammation During Neoadjuvant Chemotherapy in Stage II-III Breast Cancer: A Randomized Pilot Study. (PubMed, Arch Med Res) - "Desloratadine may improve treatment response in stage III breast cancer, supporting its potential role as a complementary agent in neoadjuvant chemotherapy."

Journal • Allergy • Breast Cancer • Immunology • Oncology • Solid Tumor • IL6 • NFKB1 • TLR4 • TNFA

Comparing Antihistamines for Chronic Urticaria: Systematic Review Dose Response and Network Meta-Analysis of Randomized Trials (ACAAI 2025) - "Sedation likely increases with higher doses, with first-generation agents among the most sedating; cetirizine, ketotifen, levocetirizine, and rupatadine among the intermediate sedating; and bilastine, desloratadine, fexofenadine, and loratadine among the least sedating. Cetirizine and loratadine are among the most effective for all components of urticaria activity, but cetirizine is intermediately sedating and loratadine has lower certainty on improving quality of life and sleep. Higher doses may have diminishing benefits and increased risks."

Retrospective data • Review • Anesthesia • Cardiovascular • CNS Disorders • Dermatology • Immunology • Pruritus • Sleep Disorder • Urticaria

Desloratadine as the selective 5HT2AR antagonist suppresses neutrophil extracellular traps formation to ameliorate diabetic peripheral neuropathy pathology. (PubMed, J Neuroinflammation) - "NETs regulated vascular dysfunction through NE/TF/HIF-1α/MMP-9/2 pathway, and DLT-mediated 5HT2AR inhibition suppressed NETs activation through PKC/NADPH/ROS pathway. Collectively, our findings revealed that 5HT2AR associates with NETs activation in DPN pathology and supported that pharmacological inhibition of 5HT2AR shows promising as a therapeutic strategy for DPN and DLT exhibits high potential in treating the disease."

Journal • Diabetes • Diabetic Neuropathy • Inflammation • Pain • HIF1A • MMP9

Desloratadine as an adjunct to isotretinoin: enhancing tolerability and adherence in acne management. (PubMed, Ann Med Surg (Lond)) - No abstract available

Journal • Acne Vulgaris

Efficacy comparison of combined montelukast-antihistamine and montelukast monotherapy in allergic rhinitis: a meta-analysis of randomized controlled trials. (PubMed, Eur Ann Allergy Clin Immunol) - "In subgroup analysis, all combinations with loratadine, desloratadine, or levocetirizine showed greater efficacy than monotherapy in improving daytime symptoms. However, the effectiveness of each drug combination varied by symptom domain. These findings may assist clinicians in selecting appropriate combination regimens based on individual symptom patterns."

Journal • Monotherapy • Retrospective data • Review • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Construction of a modified Arrhenius equation for predicting drug nitrosation in solid dosage form. (PubMed, Int J Pharm) - "The nitrosation reaction rate of desloratadine (DES) in the physical mixtures (PMs) was measured under various temperature, relative humidity, and alkaline excipient (AE) content conditions...The prediction accuracy of the modified Arrhenius equation was higher than that of the original Arrhenius equation. The modified Arrhenius equation can be applied to the nitrosation reactions of various drugs and is expected to improve the quality, safety, and efficiency of drug research, development, and manufacturing processes."

Journal

Determination of enantiomerization barriers of desloratadine and its N-oxide derivative by dynamic enantioselective high-performance liquid chromatography and off-column racemization experiments. (PubMed, J Pharm Biomed Anal) - "The results indicated that the targeted oxidation increased the activation enantiomerization barriers, thus conferring configurational stability to enantiomers. To complete the work, the absolute configuration of the enantiomers of the N-oxide derivative of desloratadine was established by comparing their experimental and theoretical chiroptical properties."

Journal • Asthma • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases

Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK-air and EAACI Methodological Committee Report. (PubMed, Allergy) - "Using patient-reported data, we evaluated different medication classes and treatments in terms of satisfaction and co-medication frequency. These results provide key insights into the acceptability of AR treatments and will contribute to future treatment guidelines."

Journal • Allergic Rhinitis • Immunology • Inflammation

Efficacy of Montelukast-Antihistamine Combination Therapy Compared with Antihistamine Monotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis. (PubMed, Clin Exp Otorhinolaryngol) - "Combinations with desloratadine and levocetirizine showed greater benefits than those with loratadine or fexofenadine. Montelukast-antihistamine combination therapy improves overall symptoms and quality of life compared with antihistamine monotherapy. The magnitude of benefit appears to vary depending on the specific antihistamine used, highlighting the potential value of individualized treatment strategies in the management of AR."

Journal • Monotherapy • Retrospective data • Review • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Ocarina II: A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (clinicaltrials.gov) - P3 | N=236 | Completed | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Completed

Head-to-Head • Trial completion • CNS Disorders • Multiple Sclerosis

Design and synthesis of photoswitchable desloratadine ligands for histamine H1 receptor photopharmacology. (PubMed, RSC Med Chem) - "Computational docking studies provide a rationale, with the binding pose of the trans and cis isomer in the H1R binding pocket potentially being inverted. While the development of effective photoswitchable ligands for H1R remains challenging, this study provides promising opportunities for future optimization to achieve optical control of this GPCR."

Journal

Efficacy of Combined Oral Isotretinoin and Desloratadine or Levocetirizine vs. Isotretinoin Monotherapy in Treating Acne Vulgaris: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Biomedicines) - "Overall, desloratadine improved tolerability and reduced mucocutaneous adverse events more than levocetirizine. Current evidence suggests that combining oral antihistamines with isotretinoin may offer therapeutic benefits in acne management, particularly in enhancing tolerability and potentially improving clinical outcomes, as reflected by significant reductions in GAGS scores and mucocutaneous adverse effects such as cheilitis, pruritus, and acne flare-ups."

Journal • Monotherapy • Retrospective data • Review • Acne Vulgaris • Dermatology • Pruritus

DETOXp: Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (clinicaltrials.gov) - P2 | N=116 | Not yet recruiting | Sponsor: Montefiore Medical Center

New P2 trial • Breast Cancer • Oncology • Pain • Solid Tumor

Clinical study on the intervention effect of vitamin D on allergic rhinitis (ChiCTR) - P=N/A | N=40 | Recruiting | Sponsor: First Affiliated Hospital of Nanchang University; First Affiliated Hospital of Nanchang University

New trial • Allergic Rhinitis • Immunology • Inflammation • IL4

Second-Generation H1-Receptor Antagonists, Mequitazine, Azelastine and Desloratadine Activate Caspase-8, Caspase-3, and Gasdermin E and Induce Cell Death Showing Pyroptotic-Like Features in Macrophages at Excessively High Concentrations. (PubMed, Biol Pharm Bull) - "Here, we examined the inflammation-modulating and cell death-inducing effects of 10 second-generation H1R antagonists on mouse intraperitoneal macrophages, which include ketotifen, mequitazine, azelastine, oxatomide, epinastine, bepotastine, fexofenadine, loratadine, levocetirizine, and desloratadine, to assess an anticipated adverse reaction. Western blotting analysis revealed that caspase-8, caspase-3, and gasdermin E (GSDME), but not gasdermin D, were cleaved and activated in the macrophages. These results suggest that second-generation H1R antagonists such as mequitazine, azelastine, and desloratadine induce pyroptotic-like cell death accompanied by caspase-8, caspase-3, and GSDME activation in macrophages."

Journal • Allergy • Immunology • Inflammation • CASP3 • CASP8 • GSDME • IL6